Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Tarsus Pharmaceuticals excels in Q4 earnings, eyes expansion opportunities

Tarsus Pharmaceuticals delivered strong financial results and positive feedback on their products. While facing challenges in payer contracts and physician adoption, they are well-positioned to capitalize on opportunities for expansion and innovation.

Tarsus Pharmaceuticals reports robust Q1 performance and eyes market expansion

Tarsus Pharmaceuticals (TARS) delivered strong Q1 results driven by XDEMVY sales and positive clinical data, with plans for further growth and optimization. While facing market challenges and seasonality, the company is focused on capitalizing on opportunities for expansion and market education. TARS aims to enhance gross-to-net margins, increase prescriber adoption, and navigate the evolving healthcare landscape.

Tarsus Pharmaceuticals excels in Q3, eyes European expansion and pipeline advancement

Tarsus Pharmaceuticals demonstrated robust performance in Q3 2024, with strong sales, expanded market access, and positive clinical data, positioning the company for continued success.
While facing challenges in market competition and international expansion, Tarsus can capitalize on opportunities in evidence generation, pipeline advancement, and patient education to drive future growth.
Overall, Tarsus Pharmaceuticals shows promise in maintaining its market position, driving product adoption, and exploring new avenues for growth and innovation in the pharmaceutical landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IRVINE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (“Tarsus” NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye, today announced that Bobak Azamian, M.D., Ph.D., CEO of Tarsus, will present an overview of the company at the Jefferies Virtual London Healthcare Conference, being held November 17-19.

Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference

IRVINE, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (“Tarsus”), a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities initially in ophthalmic conditions, today announced the closing of its initial public offering of 6,325,000 shares of its common stock at a price to the public of $16.00 per share, which includes 825,000 shares sold upon full exercise of the underwriters' option to purchase additional shares of common stock. All of the shares were offered by Tarsus. The aggregate gross proceeds to Tarsus from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $101.2 million.

Tarsus Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise by the Underwriters of Option to Purchase Additional Shares

Aligos Therapeutics

Array Technologies

Codiak Biosciences

Eastern Bankshares, Inc.

Opthea

Praxis Precision Medicines

Nine IPOs and five SPACs went public this past week, and one IPO postponed.

U.S. IPO Weekly Recap: Solar Technology Shines In A 9-IPO Week

IRVINE, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc., (“Tarsus”) a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities initially in ophthalmic conditions, today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $88.0 million, before underwriting discounts, commissions, and offering expenses payable by Tarsus. In addition, Tarsus has granted the underwriters an option for a period of 30 days to purchase up to 825,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares are being offered and sold by Tarsus.

Tarsus Pharmaceuticals Inc. Announces Pricing of Initial Public Offering

News for Tarsus Pharmaceuticals Stock (TARS)